146 related articles for article (PubMed ID: 37976072)
1. Higher-Dose Fluvoxamine and Time to Sustained Recovery in Outpatients With COVID-19: The ACTIV-6 Randomized Clinical Trial.
Stewart TG; Rebolledo PA; Mourad A; Lindsell CJ; Boulware DR; McCarthy MW; Thicklin F; Garcia Del Sol IT; Bramante CT; Lenert LA; Lim S; Williamson JC; Cardona OQ; Scott J; Schwasinger-Schmidt T; Ginde AA; Castro M; Jayaweera D; Sulkowski M; Gentile N; McTigue K; Felker GM; DeLong A; Wilder R; Rothman RL; Collins S; Dunsmore SE; Adam SJ; Hanna GJ; Shenkman E; Hernandez AF; Naggie S;
JAMA; 2023 Dec; 330(24):2354-2363. PubMed ID: 37976072
[TBL] [Abstract][Full Text] [Related]
2. Effect of Fluvoxamine vs Placebo on Time to Sustained Recovery in Outpatients With Mild to Moderate COVID-19: A Randomized Clinical Trial.
McCarthy MW; Naggie S; Boulware DR; Lindsell CJ; Stewart TG; Felker GM; Jayaweera D; Sulkowski M; Gentile N; Bramante C; Singh U; Dolor RJ; Ruiz-Unger J; Wilson S; DeLong A; Remaly A; Wilder R; Collins S; Dunsmore SE; Adam SJ; Thicklin F; Hanna G; Ginde AA; Castro M; McTigue K; Shenkman E; Hernandez AF;
JAMA; 2023 Jan; 329(4):296-305. PubMed ID: 36633838
[TBL] [Abstract][Full Text] [Related]
3. Effect of Higher-Dose Fluvoxamine vs Placebo on Time to Sustained Recovery in Outpatients with Mild to Moderate COVID-19: A Randomized Clinical Trial.
; Naggie S
medRxiv; 2023 Sep; ():. PubMed ID: 37745371
[TBL] [Abstract][Full Text] [Related]
4. Effect of Montelukast vs Placebo on Time to Sustained Recovery in Outpatients with COVID-19: The ACTIV-6 Randomized Clinical Trial.
Rothman RL; Stewart TG; Mourad A; Boulware DR; McCarthy MW; Thicklin F; Garcia Del Sol IT; Garcia JL; Bramante CT; Shah NS; Singh U; Williamson JC; Rebolledo PA; Jagannathan P; Schwasinger-Schmidt T; Ginde AA; Castro M; Jayaweera D; Sulkowski M; Gentile N; McTigue K; Felker GM; DeLong A; Wilder R; Collins S; Dunsmore SE; Adam SJ; Hanna GJ; Shenkman E; Hernandez AF; Naggie S; Lindsell CJ;
medRxiv; 2024 May; ():. PubMed ID: 38798524
[TBL] [Abstract][Full Text] [Related]
5. Effect of Higher-Dose Ivermectin for 6 Days vs Placebo on Time to Sustained Recovery in Outpatients With COVID-19: A Randomized Clinical Trial.
Naggie S; Boulware DR; Lindsell CJ; Stewart TG; Slandzicki AJ; Lim SC; Cohen J; Kavtaradze D; Amon AP; Gabriel A; Gentile N; Felker GM; Jayaweera D; McCarthy MW; Sulkowski M; Rothman RL; Wilson S; DeLong A; Remaly A; Wilder R; Collins S; Dunsmore SE; Adam SJ; Thicklin F; Hanna GJ; Ginde AA; Castro M; McTigue K; Shenkman E; Hernandez AF;
JAMA; 2023 Mar; 329(11):888-897. PubMed ID: 36807465
[TBL] [Abstract][Full Text] [Related]
6. Effect of Ivermectin vs Placebo on Time to Sustained Recovery in Outpatients With Mild to Moderate COVID-19: A Randomized Clinical Trial.
Naggie S; Boulware DR; Lindsell CJ; Stewart TG; Gentile N; Collins S; McCarthy MW; Jayaweera D; Castro M; Sulkowski M; McTigue K; Thicklin F; Felker GM; Ginde AA; Bramante CT; Slandzicki AJ; Gabriel A; Shah NS; Lenert LA; Dunsmore SE; Adam SJ; DeLong A; Hanna G; Remaly A; Wilder R; Wilson S; Shenkman E; Hernandez AF;
JAMA; 2022 Oct; 328(16):1595-1603. PubMed ID: 36269852
[TBL] [Abstract][Full Text] [Related]
7. Fluvoxamine for Outpatient Treatment of COVID-19: A Decentralized, Placebo-controlled, Randomized, Platform Clinical Trial.
McCarthy MW; Naggie S; Boulware DR; Lindsell CJ; Stewart TG; Felker GM; Jayaweera D; Sulkowski M; Gentile N; Bramante C; Singh U; Dolor RJ; Ruiz-Unger J; Wilson S; DeLong A; Remaly A; Wilder R; Collins S; Dunsmore SE; Adam SJ; Thicklin F; Hanna G; Ginde AA; Castro M; McTigue K; Shenkman E; Hernandez AF;
medRxiv; 2022 Nov; ():. PubMed ID: 36299427
[TBL] [Abstract][Full Text] [Related]
8. Effect of Ivermectin 600 μg/kg for 6 days vs Placebo on Time to Sustained Recovery in Outpatients with Mild to Moderate COVID-19: A Randomized Clinical Trial.
Naggie S; Boulware DR; Lindsell CJ; Stewart TG; Lim SC; Cohen J; Kavtaradze D; Amon AP; Gabriel A; Gentile N; Felker GM; Rothman RL; Jayaweera D; McCarthy MW; Sulkowski M; Wilson S; DeLong A; Remaly A; Wilder R; Collins S; Dunsmore SE; Adam SJ; Thicklin F; Hanna GJ; Ginde AA; Castro M; McTigue K; Shenkman E; Hernandez AF;
medRxiv; 2022 Dec; ():. PubMed ID: 36561174
[TBL] [Abstract][Full Text] [Related]
9. Effect of early treatment with fluvoxamine on risk of emergency care and hospitalisation among patients with COVID-19: the TOGETHER randomised, platform clinical trial.
Reis G; Dos Santos Moreira-Silva EA; Silva DCM; Thabane L; Milagres AC; Ferreira TS; Dos Santos CVQ; de Souza Campos VH; Nogueira AMR; de Almeida APFG; Callegari ED; de Figueiredo Neto AD; Savassi LCM; Simplicio MIC; Ribeiro LB; Oliveira R; Harari O; Forrest JI; Ruton H; Sprague S; McKay P; Glushchenko AV; Rayner CR; Lenze EJ; Reiersen AM; Guyatt GH; Mills EJ;
Lancet Glob Health; 2022 Jan; 10(1):e42-e51. PubMed ID: 34717820
[TBL] [Abstract][Full Text] [Related]
10. Virtualized clinical studies to assess the natural history and impact of gut microbiome modulation in non-hospitalized patients with mild to moderate COVID-19 a randomized, open-label, prospective study with a parallel group study evaluating the physiologic effects of KB109 on gut microbiota structure and function: a structured summary of a study protocol for a randomized controlled study.
Haran JP; Pinero JC; Zheng Y; Palma NA; Wingertzahn M
Trials; 2021 Apr; 22(1):245. PubMed ID: 33810796
[TBL] [Abstract][Full Text] [Related]
11. Ivermectin for Treatment of Mild-to-Moderate COVID-19 in the Outpatient Setting: A Decentralized, Placebo-controlled, Randomized, Platform Clinical Trial.
; Naggie S
medRxiv; 2022 Aug; ():. PubMed ID: 35982669
[TBL] [Abstract][Full Text] [Related]
12. Fluvoxamine vs Placebo and Clinical Deterioration in Outpatients With Symptomatic COVID-19: A Randomized Clinical Trial.
Lenze EJ; Mattar C; Zorumski CF; Stevens A; Schweiger J; Nicol GE; Miller JP; Yang L; Yingling M; Avidan MS; Reiersen AM
JAMA; 2020 Dec; 324(22):2292-2300. PubMed ID: 33180097
[TBL] [Abstract][Full Text] [Related]
13. Outpatient treatment of COVID-19 and incidence of post-COVID-19 condition over 10 months (COVID-OUT): a multicentre, randomised, quadruple-blind, parallel-group, phase 3 trial.
Bramante CT; Buse JB; Liebovitz DM; Nicklas JM; Puskarich MA; Cohen K; Belani HK; Anderson BJ; Huling JD; Tignanelli CJ; Thompson JL; Pullen M; Wirtz EL; Siegel LK; Proper JL; Odde DJ; Klatt NR; Sherwood NE; Lindberg SM; Karger AB; Beckman KB; Erickson SM; Fenno SL; Hartman KM; Rose MR; Mehta T; Patel B; Griffiths G; Bhat NS; Murray TA; Boulware DR;
Lancet Infect Dis; 2023 Oct; 23(10):1119-1129. PubMed ID: 37302406
[TBL] [Abstract][Full Text] [Related]
14. A randomized, double-blind, placebo-controlled phase III clinical trial to evaluate the efficacy and safety of SARS-CoV-2 vaccine (inactivated, Vero cell): a structured summary of a study protocol for a randomised controlled trial.
Akova M; Unal S
Trials; 2021 Apr; 22(1):276. PubMed ID: 33849629
[TBL] [Abstract][Full Text] [Related]
15. Safety and Efficacy of Imatinib for Hospitalized Adults with COVID-19: A structured summary of a study protocol for a randomised controlled trial.
Emadi A; Chua JV; Talwani R; Bentzen SM; Baddley J
Trials; 2020 Oct; 21(1):897. PubMed ID: 33115543
[TBL] [Abstract][Full Text] [Related]
16. Inhaled Fluticasone Furoate for Outpatient Treatment of Covid-19.
Boulware DR; Lindsell CJ; Stewart TG; Hernandez AF; Collins S; McCarthy MW; Jayaweera D; Gentile N; Castro M; Sulkowski M; McTigue K; Felker GM; Ginde AA; Dunsmore SE; Adam SJ; DeLong A; Hanna G; Remaly A; Thicklin F; Wilder R; Wilson S; Shenkman E; Naggie S;
N Engl J Med; 2023 Sep; 389(12):1085-1095. PubMed ID: 37733308
[TBL] [Abstract][Full Text] [Related]
17. Early antiviral treatment in outpatients with COVID-19 (FLARE): a structured summary of a study protocol for a randomised controlled trial.
Brown LK; Freemantle N; Breuer J; Dehbi HM; Chowdhury K; Jones G; Ikeji F; Ndoutoumou A; Santhirakumar K; Longley N; Checkley AM; Standing JF; Lowe DM
Trials; 2021 Mar; 22(1):193. PubMed ID: 33685502
[TBL] [Abstract][Full Text] [Related]
18. Effect of Antithrombotic Therapy on Clinical Outcomes in Outpatients With Clinically Stable Symptomatic COVID-19: The ACTIV-4B Randomized Clinical Trial.
Connors JM; Brooks MM; Sciurba FC; Krishnan JA; Bledsoe JR; Kindzelski A; Baucom AL; Kirwan BA; Eng H; Martin D; Zaharris E; Everett B; Castro L; Shapiro NL; Lin JY; Hou PC; Pepine CJ; Handberg E; Haight DO; Wilson JW; Majercik S; Fu Z; Zhong Y; Venugopal V; Beach S; Wisniewski S; Ridker PM;
JAMA; 2021 Nov; 326(17):1703-1712. PubMed ID: 34633405
[TBL] [Abstract][Full Text] [Related]
19. Randomized Trial of Metformin, Ivermectin, and Fluvoxamine for Covid-19.
Bramante CT; Huling JD; Tignanelli CJ; Buse JB; Liebovitz DM; Nicklas JM; Cohen K; Puskarich MA; Belani HK; Proper JL; Siegel LK; Klatt NR; Odde DJ; Luke DG; Anderson B; Karger AB; Ingraham NE; Hartman KM; Rao V; Hagen AA; Patel B; Fenno SL; Avula N; Reddy NV; Erickson SM; Lindberg S; Fricton R; Lee S; Zaman A; Saveraid HG; Tordsen WJ; Pullen MF; Biros M; Sherwood NE; Thompson JL; Boulware DR; Murray TA;
N Engl J Med; 2022 Aug; 387(7):599-610. PubMed ID: 36070710
[TBL] [Abstract][Full Text] [Related]
20. Oral Fluvoxamine With Inhaled Budesonide for Treatment of Early-Onset COVID-19 : A Randomized Platform Trial.
Reis G; Dos Santos Moreira Silva EA; Medeiros Silva DC; Thabane L; de Souza Campos VH; Ferreira TS; Quirino Dos Santos CV; Ribeiro Nogueira AM; Figueiredo Guimaraes Almeida AP; Cançado Monteiro Savassi L; de Figueiredo Neto AD; Bitarães C; Cruz Milagres A; Diniz Callegari E; Campos Simplicio MI; Barra Ribeiro L; Oliveira R; Harari O; Wilson LA; Forrest JI; Ruton H; Sprague S; McKay P; Guo CM; Guyatt GH; Rayner CR; Boulware DR; Ezer N; Lee TC; McDonald EG; Bafadhel M; Butler C; Rodrigues Silva J; Dybul M; Mills EJ;
Ann Intern Med; 2023 May; 176(5):667-675. PubMed ID: 37068273
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
